Extra energy for hearts with a genetic defect

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25078

Enrollment

Registered

2019-02-01

Start date

2019-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Cardiomyopathy

Interventions

Trimetazidine 20mg 3dd

Eligibility

Inclusion criteria

Inclusion criteria: 18-65 years old Class 5 MYH7 mutation identified by pre-symptomatic genetic screening

Exclusion criteria

Exclusion criteria: Cardiovascular disease - Hypertrophic Cardiomyopathy (Maximal Wall Thickness >15mm) - Wall motion disorders Diabetes mellitus Any absolute or relative contra-indication for MRI (i.e. metallic implants and claustrophobia) Inability to give informed consent. Severely impaired renal function with a GFR < 30 ml/min Parkinson disease and related symptoms

Design outcomes

Primary

Measure	Time frame
Myocardial energy efficiency, as measured by PET/CT and CMR	—

Secondary

Measure	Time frame
Diastolic function measured by echocardiography, volume parameters of the heart measured by CMR, exercise capacity measured by CPET, electrophysiological properties of the heart measured by ECG	—

Contacts

Public ContactBeau van Driel

Amsterdam UMC, location VUmc, Department of Physiology

b.vandriel@vumc.nl+31620673492

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)